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Abstract
Background: Diabetes Mellitus is a chronic disease and many patients of which require frequent
subcutaneous insulin injection to maintain proper blood glucose levels. Due to the inconvenience
of insulin administration, an orally active insulin replacement has long been a prime target for many
pharmaceutical companies. Demethylasterriquinone (DMAQ) B1, extracted from tropical fungus,
Pseudomassaria sp., has been reported to be an orally effective agent at lowering circulating glucose
levels in diabetic (db/db) mice; however, the cytotoxicity associated with the quinone moiety has
not been addressed thus far.
Methods: A series of hydroxyfuroic acid compounds were synthesized and tested for their
efficacies at activating human insulin receptor. Cytotoxicity to Chinese hamster ovary cells,
selectivities over insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), and fibroblast
growth factor (FGF) receptors were examined in this study.
Result and Conclusion: This study reports a new non-quinone DMAQ B1 derivative, a
hydroxyfuroic acid compound (D-410639), which is 128 fold less cytotoxic as DMAQ B1 and as
potent as compound 2, a DMAQ B1 synthetic derivative from Merck, at activating human insulin
receptor. D-410639 has little activation potential on IGF-1 receptor but is a moderate inhibitor to
EGF receptor. Structure and activity relationship of the prenylindole moiety to insulin receptor
activation is discussed.
Background
Diabetes mellitus is a chronic disease characteristic of ele-
vated blood glucose concentrations with poor glucose uti-
lization and homeostasis [1]. About 10% of all diabetic
patients are type 1 insulin dependent diabetes mellitus
(IDDM) in which insulin secreting -islets of Langerhans
are damaged or destroyed by aberrant T cells [2]. Other
diabetes cases (about 90%) are type 2 non-insulin
dependent diabetes mellitus (NIDDM) that is proceeded
by insulin resistance and frequently with metabolic syn-
drome [1]. For type 1 and late stage type 2 diabetic
patients, a common method of alleviating hyperglycemia
is by subcutaneous administration of exogenous insulin
before each meal [1,2]. Due to the inconvenience of insu-
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lin administration, it has long been a primary goal of
many pharmaceutical companies to develop an orally
active therapeutic agent for treating hyperglycemia in dia-
betic patients.
Current diabetes therapies with orally active agents fall
into five major classes, which are i) biguanide (met-
formin) that activates AMP-activated protein kinase
(AMPK) [3-6]; ii) sulfonylurea as an insulin secretogue [7-
9]; iii) peroxisome proliferator activated receptor (PPAR)
-subtype activators [10-12]; iv) -glucosidase inhibitors
[13,14]; v) dipeptidyl peptidase IV (DP-4) inhibitors [15-
18]. In addition to these targets, the insulin receptor acti-
vator is particularly interesting, because it may activate the
insulin signal transduction pathway directly without the
need of insulin, and yet it is small enough to be orally
active. Extracted from tropical fungus, Pseudomassaria sp.,
demethylasterriquinone (DMAQ) B1 is one such com-
pound [19-24] and has been shown to lower blood glu-
cose in db/db mice by activating insulin receptor's tyrosine
kinase directly [19,22]. The compound was later modified
to phenylindolyldihydroxyquinone (compound 2, by
Merck's nomenclature), with an improved efficacy (EC50
from 5.0 M to 0.3 M) [20,21]. However, DMAQ B1 and
compound 2 each has a hydroxyquinone moiety that may
facilitate free radical generation when in contact with high
energy electrons [25]. Therefore, a new insulin receptor
activator without a quinone moiety is a logical compound
to develop.
It has been reported that DMAQ B1 can be converted to
bisindolylhydroxyfuroic acids by biotransformation and
thus replaces its quinone with a furoic acid moiety (Fig.
1), but still retains its insulin receptor activation potential
[Chen et al. US Patent 6596760, 2003]. While through
medicinal chemistry, prenylindole and isoprenylindole
moieties on DMAQ B1 can be simplified to an indolyl and
a phenyl moieties resulting a phenylindolyldihydroxyqui-
none (compound 2, Fig. 1) with an improved efficacy
[20,21]. Combining these two features together, phe-
nylindolylfuroic acid derivatives were synthesized [26],
but for unknown reasons these compounds showed no
observable insulin receptor activation efficacy (data not
shown). Therefore, these phenylindolylfuroic acid deriva-
tives were not pursued further, and the bisindolylfuroic
acid scaffold is retained for further derivative develop-
ment because of its absence of a quinone moiety. The iso-
prenyl chain on the isoprenylindole is not essential for the
insulin receptor activation in our setting, and was omitted
in subsequent derivatives (Fig. 1). A new class of insulin
receptor activators was discovered under such circum-
stances. We report a new hydroxyfuroic acid compound,
D-410639, that possesses insulin receptor activation
property as well as inhibition for epidermal growth factor
receptor (EGF-R/ErbB1).
Methods
Materials and Chemicals
The CHO cell line overexpressing recombinant human
insulin receptor was kindly provided by Dr. Richard Roth
at Stanford University. Scintillation cocktail and -P33 ATP
were purchased from Perkin-Elmer (Wellesley, MA). P81
phosphocellulose paper is a product of Millipore (Biller-
ica, MA). Ab-3 antibody is a product of Upstate (Char-
lottesville, VA). Recombinant human IGF-1 receptor,
EGF-R (ErbB1), and FGF-R3 were purchased from R&D
systems (Minneapolis, MN). DMAQ B1 and Compound 2
of Merck were obtained from Calbiochem (La Jolla, CA).
Other chemicals were purchased from Sigma-Aldrich (St.
Louis, MO).
Syntheses of Hydroxyfuroic Acid Compounds
The synthesis strategy of hydroxyfuroic acids is summa-
rized and presented in Fig. 2, as described below.
Furan diester 3
A 615 mL of benzene solution containing 170 mmol
dimethyl diglycolate 1 and 230 mmol indolylglyloxalate
2 was added drop wise to a 720 mL of refluxing benzene
suspension containing t-BuOK, prepared from dissolving
potassium (4.5 molar eqs vs 1) in 765 mmol t-BuOH.
After 2.5 h, the cooled mixture was acidified and then 500
mL of ethyl acetate was added while under stirring. The
organic layer was separated, concentrated, added with
1550 mL of DMF, and then treated with MeI (572 mmol)
and K2CO3 (770 mmol). After 21 h of stirring, residues in
the mixture was filtered off and the filtrate was evaporated
under reduced pressure, followed by partitioning with
CH2Cl2/H2O. The separated organic layer was condensed
and the residue was purified by chromatography on a sil-
ica gel to yield 3 (76.5 mmol, 45%).
Furan diester 4
Fifty-seven mmol of 3 and 110 mmol of DDQ was mixed
in 813 mL of CH2Cl2/H2O (18:1, v/v) and stirred at room
temperature for 21 h. The resulting mixture was quenched
with 5% aqueous Na2CO3, followed by partitioning with
CH2Cl2/H2O. The separated organic layer was condensed
and the residue was purified by silica gel chromatography
to yield 4 (34.2 mmol, 60%).
Furan diester 5
A 460 mL 2-butanone solution containing 46 mmol 4 was
treated with TsCl (92 mmol) and K2CO3 (137 mmol).
After 2 h refluxing, additional 46 mmol TsCl and 69
mmol K2CO3 were added and refluxed further overnight.
The mixture was filtered and the filtrate was evaporated to
leave a solidified residue. The residue was triturated over
methanol to form a white powder suspension. The pow-
der was isolated by filtration and dried to give 5 (42.3
mmol, 92%). Alternatively, 5 can be prepared by metal-Journal of Biomedical Science 2009, 16:68 http://www.jbiomedsci.com/content/16/1/68
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catalyzed cross coupling of triflorosulfonated 6 and an N-
tosyl-3-iodoindole derived boric acid 7 (1.5 molar eqs) in
refluxing THF (20 mL/g) which had a 66% yield.
Furan diacid 8
A solution containing 25.4 mmol of 5 in 280 mL metha-
nol and 23 mL H2O was added with 177.7 mmol of lith-
ium hydroxide at 25°C and stirred for 5 h. The mixture
was acidified with 3 N HCl, followed by evaporation. The
residue was extracted with ethyl acetate and washed with
H2O. The separated organic layer was evaporated to give 8
(25.2 mmol, 99%).
Furan halfester 9
Methyl chloroformate (22.0 mmol) predissolved in 30
mL dichloromethane was added to a 100 mL dichlo-
romethane solution containing 22.0 mmol of 8 and 23.1
mmol of triethylamine at 0°C. After 1 h stirring at 0°C,
DMAP (2.6 mmol) was added and stirred at 0°C for 1 h
and 18 h at room temperature. The resulting solution was
then acidified, extracted with dichloromethane, and sol-
vent evaporated. The residue was purified by silica gel
chromatography to yield 9 (13.2 mmol, 60%).
Active receptor tyrosine kinase activators Figure 1
Active receptor tyrosine kinase activators. Demethylasterriquinone B1 is extracted from tropical fungus, Pseudomassaria 
sp., and can be transformed to hydroxyfuroic acid which still retains insulin receptor activation capability. Compound 2 and D-
410639 are derived from Demethylasterriquinone B1 and hydroxyfuroic acid, respectively.
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Furan bisiindoles 11
Oxalyl chloride (10 mL/g) was added to 9 (12.2 mmol)
and stirred for 20 minutes. The mixture was condensed
under vacuum to give the acyl chloride of 9. In a separated
flask, a 60 mL dichloromethane solution containing 12.4
mmol of the 7'-substituted indoles 10 was added with
Et2AlCl (1 M in hexane, 30 mmol) at 0°C and stirred for
0.5 h before 50 mL dichloromethane solution containing
the aforementioned acyl chloride 9 was added. After 1 h
stirring at 0°C and 14 h at room temperature, the reaction
was quenched with 3 N HCl. The separated organic layer
was condensed and the residue was purified by silica gel
chromatography to yield 11 (5166% yield).
Preparation of bisindolylhydroxyfuroic acids Figure 2
Preparation of bisindolylhydroxyfuroic acids. i. a) K, t-BuOH, benzene; b) MeI, N,N-dimethylformamide (DMF), 45% (two 
steps); ii. DDQ, CH2Cl2/H2O (18/1, v/v); 46%; iii. TsCl, 2-butanone, K2CO3, reflux, 86%; iv. OH-, MeOH, H2O, 95%; v. PdCl2 
(PPh3)2 (0.1 eq), Na2CO3 (3.0 eq), DMF, 90°C, 12 h, 66%; vi. ClCO2Me (100 mol %), NEt3 (107 mol %), CH2Cl2 (6 mL/mmol 8), 
DMAP (12 mol %), 60%; vii. a) oxalyl chloride, DMAP (cat.), r.t.; b) 7-substituted indole 10, Et2AlCl, CHCl3, 5166%; viii. BCl3, 
CH2Cl2,0°C  r.t.; 8085%; ix. 5% NaOH in methanol, reflux, 6670%.
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Furan bisindoles 12
A 50 mL dichloromethane solution containing 5.3 mmol
4 was added with BCl3 (1 M in hexane, 35 mmol) at 0°C.
The reaction mixture was stirred at 0°C for 0.5 h and at
room temperature for 3 h, and then diluted with addi-
tional 200 mL dichloromethane. After another 0.5 h stir-
ring, the mixture was quenched on ice water and the
separated organic layer was condensed. The residue was
purified by silica gel chromatography and yielded 12
(8085% yield).
Bisindolylhydroxyfuroic acids (D-410637D-410639 and D-
410641D-410644)
A methanol solution (1015 mL/g) containing 0.11 g of 12
was added with 1.0 mL of 5% aqueous NaOH and
refluxed for 0.5 h. The mixture was concentrated, acidified
with 3 N HCl, and then extracted with ethyl acetate. The
extract was washed with brine, dried, and solvent evapo-
rated. The residue was purified by silica gel chromatogra-
phy to give the titled compounds with 6670% yield.
Bisindolylhydroxythiophene carboxylic acid (D-410640)
The compound was obtained with 9.5% overall yield by
applying the same methods described in furoic acid deriv-
ative (D-410639) but using thiodiglycolic acid dimethyl
ester and 2 as the starting materials.
Physical properties of bisindolylhydroxyfuroic acid com-
pounds are listed as following:
D-410637, a yellow powder, mp 140142°C (ethyl ace-
tate);  1H-NMR (500 MHz, 6d-DMSO)  : 1.841.88 (m,
2H), 2.95 (t, J = 7.4 Hz, 2H), 3.51 (t, J = 6.5 Hz, 2H),
7.027.05 (m, 1H), 7.117.15 (m, 2H), 7.187.21 (m, 1H),
7.46 (d, J = 8.0 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.627.63
(m, 1H), 8.27 (d, J = 7.5 Hz, 1H), 8.66 (d, J = 2.2 Hz, 1H).
Mass spectrometry (MS) (ESI, negative mode): 443.2 (M+-
H); high resolution mass spectrometry (HREIMS): Calcu-
lated for C25H20N2O6 (M+) 444.4361, found 444.4358.
D-410638, a yellow powder, mp 145147°C (ethyl ace-
tate);  1H-NMR (500 MHz, 6d-acetone) : 1.631.65 (m,
2H), 1.841.86 (m, 2H), 3.01 (t, J = 7.5 Hz, 2H), 3.64 (t, J
= 6.5 Hz, 2H), 7.077.08 (m, 1H), 7.157.17 (m, 2H),
7.237.25 (m, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.357.36 (m,
1H), 7.48 (d, J = 8.0 Hz, 1H), 7.7980 (m, 1H), 8.35 (d, J
= 8.0 Hz, 1H), 8.60 (br s, 1H), 8.90 (br s, 1H). MS (ESI,
negative mode): 457.2 (M+-H); HREIMS: Calculated for
C26H22N2O6 (M+) 458.1478, found 458.1459.
D-410639, a yellow powder, mp 158160°C (ethyl ace-
tate);  1H-NMR (500 MHz, 6d-acetone) : 1.531.55 (m,
2H), 1.61 (t, J = 7.2 Hz, 2H), 1.82 (t, J = 7.4 Hz, 2H), 3.01
(t, J = 7.8 Hz, 2H), 3.58 (t, J = 6.2 Hz, 2H), 7.107.11 (m,
1H), 7.187.20 (m, 2H), 7.267.28 (m, 1H), 7.51 (d, J = 8.0
Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 2.5 Hz, 1H),
8.38 (d, J = 7.9 Hz, 1H), 8.84 (d, J = 3.2 Hz, 1H), 10.7 (br
s, 1H), 11.4 (br s, 1H). MS (ESI): 473.0 (M++H); HREIMS:
Calculated for C27H24N2O6  (M+) 472.1634, found
472.1639.
D-410640, a yellow powder, mp 144146°C (ethyl ace-
tate); 1H-NMR (6d-DMSO) : 1.391.40 (m, 2H), 1.471.49
(m, 2H), 1.661.69 (m, 2H), 2.91 (t, J = 7.6 Hz, 2H), 3.39
(t, J = 7.1 Hz, 2H), 6.956.98 (m, 1H), 7.067.10 (m, 2H),
7.157.18 (m, 1H), 7.397.43 (m, 2H), 7.52 (s, 1H), 8.13
(d, J = 7.9 Hz, 1H), 8.41 (s, 1H), 11.2 (br s, 1H), 12.4 (br
s, 1H), 13.2 (br s, 1H). MS (ESI): 489.0 (M++H); HREIMS:
Calculated for C27H24N2O5S (M+) 488.1406, found
488.1421.
D-410641, an amorphous oil; 1H-NMR (4d-MeOH)  :
0.90 (m, 3H), 1.39 (br s, 4H), 1.73 (br s, 2H), 2.90 (br s,
2H), 7.04 (m, 2H), 7.11 (m, 1H), 7.17 (m, 1H), 7.39 (d,
J = 8.1 1H), 7.59 (d, J = 8.7, 2H), 8.28 (d, J = 7.8 Hz, 1H),
8.86 (br s, 1H). MS (ESI): 457.0 (M++H); HREIMS: Calcu-
lated for C27H24N2O5 (M+) 456.1685, found 456.1693.
D-410642, a yellow powder, mp 141143°C (ethyl ace-
tate);  1H-NMR (500 MHz, 6d-acetone) : 1.501.53 (m,
2H), 1.741.76 (m, 1H), 1.851.89 (m, 2H), 3.01 (t, J = 7.9
Hz, 2H), 3.633.67 (m, 4H), 7.097.12 (m, 1H), 7.177.21
(m, 2H), 7.257.28 (m, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.68
(d, J = 8.0 Hz, 1H), 7.79 (d, J = 2.6 Hz, 1H), 8.38 (d, J =
7.8 Hz, 1H), 8.84 (d, J = 3.1 Hz, 1H), 10.68 (br s,
1H),11.52 (br s, 1H). MS (ESI): 503.0 (M++H); HREIMS:
Calculated for C28H26N2O7  (M+) 502.1740, found
502.1746.
D-410643, an amorphous oil; 1H-NMR (500 MHz, 6d-
acetone) : 1.74 (d, J = 7.6 Hz, 2H), 1.92 (d, J = 2.1 Hz,
2H), 2.38 (t, J = 7.5 Hz, 2H), 3.02 (t, J = 7.5 Hz, 2H),
7.087.11 (m, 1H), 7.177.21 (m, 2H), 7.257.27 (m, 1H),
7.50 (d, J = 8.1 Hz, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.77 (d,
J = 2.4 Hz, 1H), 8.37 (d, J = 7.8 Hz, 1H), 8.83 (d, J = 3.0
Hz, 1H), 10.66 (br s, 1H),11.44 (br s, 1H). MS (ESI):
487.0 (M++H); HREIMS: Calculated for C27H22N2O7 (M+)
486.1427, found 486.1432.
D-410644, an amorphous oil; 1H-NMR (6d-acetone) :
3.25 (t, J = 7.0 Hz, 2H), 3.6 (t, J = 7.0 Hz, 2H), 7.09 (m,
1H), 7.17 (m, 1H), 7.26 (m, 2H), 7.50 (d, J = 8.1 Hz, 1H),
7.67 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 2.6 Hz, 1H), 8.39 (d,
J = 7.6 Hz, 1H), 8.85 (d, J = 3.1 Hz, 1H), 10.7 (br s, 1H),
11.5 (br s, 1H). MS (ESI): 459.0 (M++H). HREIMS: Calcu-
lated for C25H18N2O7 (M+) 458.1114, found 458.1109.
Insulin Receptor Activation Assay
The insulin receptor activation assay is based on the assay
described by Zhang et al. [19-21] with minor modifica-Journal of Biomedical Science 2009, 16:68 http://www.jbiomedsci.com/content/16/1/68
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tions. Briefly, approximately 100,000 CHO cells overex-
pressing human recombinant insulin receptor were
suspended in 100 l of Ham's F-12 medium containing
10% fetal bovine serum (FBS) and seeded into each well
of a 96-well plate. Cells were incubated at 37°C with 5%
CO2 aeration overnight. CHO cells were rinsed with phos-
phate buffered saline (PBS) 3 times and starved in serum
free Ham's F-12 medium for 2 hours before being stimu-
lated with desired concentration of insulin or test com-
pound for 20 minutes. Test compounds were predissolved
in DMSO as 100× stocks and serially diluted when neces-
sary. Stimulated CHO cells were then rinsed 3 times with
PBS and lysed in 60 l of lysis buffer. Fifty l of the lysate
was transferred to a well on a Flexible Assay Plate that was
precoated with Ab-3 antibody recognizing the -subunit
of insulin receptor. The well was then rinsed 3 times with
Tris buffered saline (TBS) containing 0.1% Tween20 and
thrown dried by hand before 10 l of tyrosine kinase reac-
tion mixture (50 mM HEPES, pH7.4, 5 mM MgCl2, 5 mM
MnCl2, 1 mg/mL polyGlu/Tyr and 250,000 cpm -P33
ATP/well) was added. The reaction was carried out at
25°C for 40 minutes and terminated by adding 50 l ice
cold 100 mM phosphoric acid. Fifty l of the stopped
reaction mixture was then transferred to an inch square
P81 paper. The P81 paper was air dried and then rinsed in
Millipore water 5 times to remove leftover radioactive ATP
and product ADP. Five mL of scintillation cocktail was
added to the paper before the count was read in a liquid
scintillation counter.
IGF-1 Receptor Tyrosine Kinase Activity Assay
The reaction was carried out at pH7.0 in the presence of
50 mM HEPES, 5 mM MgCl2, 0.01 g/l polyGlu/Tyr sub-
strate, 5 mM DTT, 250,000 cpm radioactive ATP, and 0.4
ng/l IGF-1R tyrosine kinase with a final volume of 100 l
at 37°C for 10 minutes. The IGF-1 receptor tyrosine
kinase reaction was carried out with subsaturating con-
centrations of substrates for better sensitivity to activator
or inhibitor influence. Test compound D-410639 was pre-
dissolved in DMSO as 20× stock. The reaction was
stopped by the addition of 100 l of 25 mM EDTA (pH8),
and 85 l of the stopped reaction mix was blotted on an
inch square P81 paper. P81 paper was air dried before
rinsed 5 times in Millipore water to remove non-protein
phosphorus. Five mL scintillation cocktail was added to
the P81 paper before the counts were read with a liquid
scintillation counter.
EGF Receptor (ErbB1) Tyrosine Kinase Activity Assay
The reaction condition of EGF receptor (ErbB1) was simi-
lar to that of IGF-1 receptor reaction except 0.04 g/l pol-
yGlu/Tyr substrate and 0.3 ng/l EGF receptor (ErbB1)
were used, and the reaction time was 15 minutes. All other
conditions or processes were the same. The EGF receptor
tyrosine kinase reaction was carried out with subsaturat-
ing concentrations of substrates for better sensitivity to
activator or inhibitor influence.
FGF Receptor 3 Tyrosine Kinase Activity Assay
The reaction condition of FGF receptor 3 was similar to
that of EGF receptor except 0.1 g/l polyGlu/Tyr sub-
strate and 0.05 ng/l FGF-receptor 3 were used instead. All
other conditions or processes were the same. The FGF
receptor 3 tyrosine kinase reaction was carried out with
subsaturating concentrations of substrates for better sensi-
tivity to activator or inhibitor influence.
Cytotoxicity Assay
Approximately 5,000 CHO cells suspended in 100 l D-
MEM containing 10% FBS were seeded in each well of a
96-well plate overnight before the cytotoxicity assay. Test
compounds were predissolved as 10× solution in 10%
DMSO, 10% ethanol, 80% PBS and 10 l of this 10× test
compound solution were added to each well. After 24
hours incubation, medium containing test compound
was removed by aspiration and 3 rinses of PBS. One hun-
dred l of serum medium was replenished before 20 l
methylthiazolyldiphenyl-tetrazolium bromide (MTT, 2.5
mg/mL) and 1 l phenazine methosulfate (PMS, 50 M)
was added to each well before a 3-hour further incubation
at 37°C. Optical density at 450 nm was measured with an
ELISA reader. LC50 is defined as the concentration of com-
pound that causes 50% drop of cell viability in this test.
Determination of EC50 or IC50
The 50% effective or inhibition concentrations were deter-
mined with the standard curve analysis of SigmaPlot 8.02.
The nonlinear regression equation is y = min+(max-min)/
(1+(x/EC50)Hill Slope) where y is the observed responses; x
is the dose concentrations; max and min are approxi-
mated by the program automatically during the calcula-
tion.
Results
Insulin receptor tyrosine kinase activation
To validate the insulin receptor activation assay, dose
response curve of bovine insulin was determined. The
EC50 of bovine insulin is approximately 5.1 nM, which is
reasonable comparing to 1 nM reported by Liu et al. [21].
In subsequent experiments, we routinely included 1, 10,
and 100 nM insulin as standard reference. Since 10 nM
insulin showed more consistent potency, we chose 10 nM
insulin as the standard concentration serving as a refer-
ence point for all experiments. For simplicity, the effica-
cies of hydroxyfuroic acid compounds were expressed as
percentage of activities comparing to the response pro-
vided by 10 nM insulin stimulation in parallel. To distin-
guish human insulin receptor kinase from other tyrosine
kinases in CHO cells, Ab-3, a human insulin receptor -
subunit specific monoclonal antibody, was used to absorbJournal of Biomedical Science 2009, 16:68 http://www.jbiomedsci.com/content/16/1/68
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insulin receptor from the CHO cell lysate, so the radioac-
tivity catalyzed by captured tyrosine kinase is attributable
to insulin receptor tyrosine kinase activity.
Non-quinone hydroxyfuroic acid as insulin receptor 
activator
Various hydroxyalkyl side chains were derived to test the
best structure on the 7-indolyl position. Hydroxyl or car-
boxyl derivatives of 3-carbon or longer side chain showed
sustained insulin receptor activation potential (Table 1).
A side chain of 5-carbon alcohol showed better efficacy
(D-410639, 7289%) over 4- or 3- carbon alcohol deriva-
tives (D-410638, 31.3%; D-410637, 18.9%, respectively).
The hydroxyl group is important because its non-hydroxyl
counterpart (D-410641) achieved only 48.6% efficacy.
One additional hydroxymethyl side chain (D-410642)
does not help the efficacy, since it remains low at 40.4%;
nor oxidation of the hydroxyl group to a carboxyl group,
because it offers no substantial improvement to the effica-
cies (D-410643, 48.9%; D-410644, 21.9%, respectively).
Therefore, a 5-carbon hydroxypentyl side chain on the 7-
indolyl position offers the best insulin receptor activation
efficacy thus far, and consistently we have observed high-
est receptor responses associated with D-410639 stimula-
tion when compared to other compounds in multiple
occasions (data not shown).
In a separate experiment, the potency of D-410639 was
compared to that of compound 2, as shown in Fig. 3. In
this assay, the maximal activity of either compound
reached 6670% of receptor kinase activation provided by
10 nM insulin and the EC50 are 33 and 39 M for D-
410639 and compound 2, respectively. The EC50 for com-
pound 2 is about 2-order different from 0.3 M reported
previously by Merck's group [20,21]. The exact reason for
this discrepancy is not clear, as our compound 2 was also
obtained from Merck, however, a logical explanation is
that different laboratory practice resulted in different out-
comes but under identical conditions, D-410639 is as
potent as compound 2.
D-410640 is a thiophene equivalent of D-410639, with a
higher yield advantage during the synthesis process, so its
efficacy on insulin receptor activation was examined.
Unfortunately, the efficacy of D-410640 levels off at 50
M and tapers off by 100 M, suggesting a negative effect
associated with the thiophene moiety at mid to high M
range. As a result, thiophene derivatives were not pursued
further (Fig. 4).
Cytotoxicity and growth factor receptor selectivity of D-
410639
Because D-410639 is a non-quinone derivative, its cyto-
toxicity against quinone derivatives, i.e., DMAQ B1 and
compound 2, on Chinese hamster ovary (CHO) tissue cell
culture were examined. DMAQ B1 showed the strongest
cytotoxic effect (LC50  = 2.3 M), while compound 2
improved the cytotoxicity to 66.5 M. As one may expect,
D-410639 further alleviated the cytotoxicity to approxi-
mately 296 M, attributable to the replacement of the
dihydroxyquinone moiety with a hydroxyfuroic acid moi-
ety (Fig. 5).
Asterriquinone are known for its potential to activate
insulin-like growth factor-1 (IGF-1) and epidermal
growth factor (EGF) receptors at mid to high M range
[19,22]; therefore, it is important to characterize D-
410639's activation potential at these growth factor recep-
tors. The IGF-1 receptor activity was increased by about
6070% from the base line with mid M of D-410639 (Fig.
6A) and the non-linear EC50 fitting curve program sug-
gested EC50 to be 17 M, but the statistical t-test of the
EC50 itself is not significant (p = 0.63) due to large varia-
tion.
Unlike the minor activation potential of DMAQ-B1 on
EGF receptor (ErbB1) as reported by Zhang et al. [19], D-
Table 1: Relative insulin receptor activation potentials of hydroxyfuroic acid compounds with various prenylindole moiety.
Compound Side Chain Study 1a % activationb Study 2a % activationb
D-410637 (CH2)2CH2OH 18.9
D-410638 (CH2)3CH2OH 31.3
D-410639 (CH2)4CH2OH 5590 89.4 1181 72.3
D-410641 (CH2)4CH3 792.7 48.6
D-410642 (CH2)3CH(CH2OH)2 659.3 40.4
D-410643 (CH2)4COOH 799 48.9
D-410644 (CH2)2COOH 357.3 21.9
Insulin  10 nM 6250 1632.5
a Data in these columns are cpm, representing phosphoryl incorporation by tyrosine kinase activities. Study 1 and 2 are separate experiments each 
with a 10 nM insulin and a 100 M D-410639 control for internal reference. The test concentration for hydroxyfuroic acid compounds was 100 M. 
See Materials and Methods for detail.
b Percentage of tyrosine kinase activities as compared to that offered by 10 nM insulin stimulation, presented at the bottom row.Journal of Biomedical Science 2009, 16:68 http://www.jbiomedsci.com/content/16/1/68
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410639 demonstrated a substantial inhibitory property
on EGF-R (ErbB1) tyrosine kinase activity, with the IC50
being estimated to be 1.8 M (Fig. 6B). Interestingly, D-
410639 is also an effective inhibitor on fibroblast growth
factor (FGF) receptor 3 tyrosine kinase with the IC50 pro-
jected at 26.5 M (Fig. 6C).
Discussion
This study presents a new class of insulin receptor activa-
tor, compounds with a hydroxyfuroic acid scaffold,
which, along with DMAQ B1 and Merck's compound 2,
can activate insulin receptor in the absence of insulin. In
contrast to the report by Wood et al. [27], we found the
dihydroxyquinone moiety is replaceable by a hydroxyfu-
roic acid moiety without losing much of the insulin recep-
tor activation capability (Fig. 3). At the meantime,
without a dihydroxyquinone moiety, the cytotoxicity
effect of insulin receptor activator on CHO cells was
reduced by 128 fold (Fig. 5) as compared to DMAQ B1.
Perhaps the most intriguing part of these new insulin
receptor activators is that dihydroxyquinone derivatives
can tolerate the replacement of isoprenylindole by a phe-
nyl group so well that compound 2 of Merck has an even
better efficacy than original DMAQ B1 [20,21]. However,
the same does not apply to hydroxyfuroic acid com-
pounds; a phenyl substitution for the isoprenylindole on
a hydroxyfuroic acid compound renders these com-
pounds inactive completely. That is, DMAQ B1 may be
transformed to a hydroxyfuroic acid derivative or simpli-
fied to compound 2 (phenylindolylhydroxyquinone) and
retains its insulin receptor activation potential, but these
two features cannot be combined together (Fig 2). The
reason for this incompatibility may be too difficult to be
demonstrated by the medicinal chemistry approach; per-
haps X-ray crystallography of these compounds with an
insulin receptor may have a better chance of answering
this question. Despite insulin receptor tyrosine kinase
domain structure has been solved long ago [28] and the
activation mechanism is well studied [29], the exact bind-
ing pocket for DMAQ B1 on insulin receptor remains
unknown. Though this site has been postulated [30], how
does the binding of an insulin receptor activator com-
pound trigger receptor tyrosine kinase activation remains
to be illustrated.
The prenylindole moiety is important for bioactivities of
asterriquinone and compounds with a hydroxyfuroic acid
scaffold (Table 1), because: i) diisoprenylindolylasterriq-
uinone (L-767827 in ref. [19]) showed no insulin recep-
tor tyrosine kinase activation potential; ii) in a series of
test compounds (D-410637, D-410638 and D-410639),
the compound's efficacy is dictated by the length of the
hydroxyalkyl chain, which is an oxidized derivative of the
prenyl chain. Presumably, this alkyl side chain may have
a corresponding binding pocket on the insulin receptor,
and the pocket is probably hydrophobic in nature because
pentanol (D-410639) or pentyl (D-410641) side chains
are both well accommodated while shorter butanol (D-
410638) or propanol (D-410637) side chains are well tol-
erated but with lower efficacies. At the distal end of this
side chain pocket, insulin receptor prefers one hydroxyl
group because the activity improves with the addition of
a hydroxyl group on the pentyl chain, but the addition of
a second hydroxymethyl group (D-410642) or oxidation
of the terminal alcohol group to a carboxyl group (D-
410643) offers no improvement. Therefore, a hydrophilic
group and potentially a hydrogen bond donor or acceptor
is likely preferred at the distal end of this pocket. How-
ever, compound 2 of Merck is a noticeable exception
which does not have a prenyl or an alkyl chain on its
methylindole moiety. How does compound 2 activate
insulin receptor tyrosine kinase without a 7-prenyl or 7-
alkyl chain remains to be illustrated.
The exact nature or importance of the isoprenyl chain on
DMAQ B1 is not known, since we did not have any com-
pound for direct comparison. But the isoprenylindole
moiety can be simplified to an indole and still retains sig-
nificant activity (D-410639 and all other compounds
listed in Table 1), suggesting it is not essential for insulin
receptor activation with a hydroxyfuroic acid as the scaf-
fold. If this assumption is false, all those hydroxyfuroic
Insulin receptor tyrosine kinase activation curves by com- pound D-410639 and compound 2 Figure 3
Insulin receptor tyrosine kinase activation curves by 
compound D-410639 and compound 2. The activation 
assays were determined side by side, and both compounds 
plateau out at about 60% level achieved by 10 nM insulin with 
EC50 being 32.9 M for D-410639 and 38.9 M for com-
pound 2. Error bars indicate standard deviations.
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Dose response curves of compound D-410639 and D-410640 Figure 4
Dose response curves of compound D-410639 and D-410640. Receptor tyrosine kinase activation was normalized 
against 10 nM insulin activation. Each curve is an average of 3 determinations and the error bars indicate standard deviations.
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Cytotoxicity test of DMAQ-B1, compound 2 and D-410639 on CHO cells Figure 5
Cytotoxicity test of DMAQ-B1, compound 2 and D-410639 on CHO cells. CHO cells were treated with various con-
centrations of test compounds and their viability was measured with the use of MTT. LC50 for DMAQ-B1, compound 2, and D-
410639 are 2.3 M, 66.5 M, and 295.9 M, respectively. Error bars indicate standard error of the mean (SEM). See Materials 
and Methods for detail.
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Dose effect of compound D-410639 on the tyrosine kinase activities of IGF-1 receptor (panel A), EGF receptor (ErbB1, panel  B), and FGF receptor 3 (panel C) Figure 6
Dose effect of compound D-410639 on the tyrosine kinase activities of IGF-1 receptor (panel A), EGF receptor 
(ErbB1, panel B), and FGF receptor 3 (panel C). Receptor tyrosine kinase activation was compared to the control which 
received a blank placebo, and the base line control was considered as 100% activity. Error bars indicate standard deviations. 
Projected EC50 for IGF-1 receptor was 16.9 M, but the EC50 is not statistically significant. The IC50 for EGF receptor (ErbB1) 
and FGF receptor 3 are 1.8 M and 26.5 M, respectively. See Materials and Methods for detail.
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acid compounds in Table 1 would have shown no activity
essentially. Therefore, it is suggested that isoprenyl group
is not likely to play a significant role as other features at
activating insulinreceptor.
Another interesting aspect of D-410639 is its inhibitory
potential at epidermal growth factor receptor. Studies
have shown that EGF signal plays a major role at the
development of vascular dysfunction in diabetic animals
[31,32], and thus inhibition of EGF receptor in diabetic
subjects may be useful at alleviating vascular complica-
tion associated with the hyperglycemic condition [33].
Therefore, a dual function compound like D-410639 with
dual properties, activator for insulin receptor and antago-
nist for EGF receptor, is rather interesting and deserves fur-
ther study.
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